-50.8%
INTU vs MRNA
+485.7%
-536.5%
-63.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.8% | +5.4% | -2.6% | +2.7% |
| 7D | -3.3% | -1.1% | -2.3% | -3.3% |
| 30D | -3.9% | +126.1% | -130.0% | -6.7% |
| 3M | +16.6% | +190.0% | -173.4% | +13.1% |
| 6M | -26.4% | +157.2% | -183.7% | -28.3% |
| YTD | -51.0% | +388.2% | -439.2% | -53.6% |
| 1Y | -50.8% | +467.0% | -517.8% | -54.7% |
| All | -50.8% | +485.7% | -536.5% | -54.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling